If you are a UMMC patient interested in monoclonal antibody (mAb) treatment, please consult your UMMC provider for a referral.
To qualify for treatment, UMMC patients must:
About Monoclonal Antibody (mAb) TreatmentThe FDA has approved the REGEN-COV™ (casirivimab/imdevimab) monoclonal antibody treatment for some adults and children with mild to moderate COVID-19. When started early in the disease, treatment with antibodies may help keep people from getting worse. The treatment is not approved for cases that have advanced past the mild to moderate stage, so it’s important to begin treatment as soon as possible.
What to expect during treatmentThe antibodies are given in shots or IVs. Treatment does not require admission to the hospital. This will take up to three hours. This includes preparation for treatment, the treatment itself, and time to observe you after treatment.
Note: Monoclonal antibody treatments should not be used for patients who are hospitalized with COVID-19, require oxygen therapy for COVID-19, or have an increase in baseline oxygen flow rate due to COVID-19.